Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML
对于不适合接受强化化疗的异柠檬酸脱氢酶突变型急性髓系白血病患者,一线三联疗法(包括去甲基化药物、维奈托克和异柠檬酸脱氢酶抑制剂)的疗效
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-25-00640
DiNardo, Courtney D; Marvin-Peek, Jennifer; Loghavi, Sanam; Takahashi, Koichi; Issa, Ghayas C; Jen, Wei-Ying; Daver, Naval G; Reville, Patrick K; Short, Nicholas J; Sasaki, Koji; Mullin, Jillian K; Bradley, Corey A; Borthakur, Gautam; Maiti, Abhishek; Alvarado, Yesid; Pemmaraju, Naveen; Abbas, Hussein A; Hammond, Danielle E; Haddad, Fadi; Bravo, Guillermo Montalban; Chien, Kelly S; Yilmaz, Musa; Kornblau, Steven M; Jabbour, Elias; Ravandi, Farhad; Kadia, Tapan; Garcia-Manero, Guillermo; Konopleva, Marina Y; Kantarjian, Hagop M